GAA
Pompe Disease, Glycogen Storage Disease Type II: GAA Deletion/Duplication MLPA
Pompe Disease, Glycogen Storage Disease Type II: GAA Deletion/Duplication MLPA
GAA deletion/duplicaion is a molecular test used to identify copy number variants and to confirm the diagnosis of Pompe disease, or glycogen storage disease type II. This test can also identify disease-causing variants within a family to facilitate carrier screening.
Pompe disease\, glycogen storage disease type II
Clinical Information
Pompe disease is caused by a deficiency of the enzyme alpha-glucosidase (GAA), an enzyme that at normal levels will breakdown glycogen in the body. Infantile-onset Pompe disease is characterized by hypotonia, generalized muscle weakness and hypertrophic cardiomyopathy. Death generally occurs within the first year of life due to cardiac and respiratory failure. The later-onset form shows greater variability with a slowly progressive muscle weakness and respiratory insufficiency. The degree of enzyme deficiency is generally related to the severity and age of onset.
Technical Information
Specimen Requirements
Transport Instructions
Associated Tests
- Comprehensive Cardiac NGS Panel
- Comprehensive Pulmonary NGS Panel
- Lysosomal Storage Disease Enzyme Panel (DBS)
- Pompe Disease, Glycogen Storage Disease II: Glucose Tetrasaccharide (Glc4) Urine Monitoring
- Pompe Disease, Glycogen Storage Disease Type II: Alpha-glucosidase Enzyme Analysis
- Pompe Disease, Glycogen Storage Disease Type II: GAA Sequencing
- Rhabdomyolysis & Metabolic Myopathies NGS Panel
Connect With Our Experts
Call 1-800-473-9411 to speak with our team of laboratory genetic counselors for questions or additional information.
Robin Fletcher, MS, CGC
Falecia Thomas, MS, CGC
Alex Finley, MS, CGC
